Exp Clin Endocrinol Diabetes 2020; 128(01): 8-14
DOI: 10.1055/a-0643-4692
Article
© Georg Thieme Verlag KG Stuttgart · New York

Thyroid Peroxidase Antibody is Associated with Plasma Homocysteine Levels in Patients with Graves’ Disease

Fang Li
1  Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
,
Gulibositan Aji
1  Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
,
Yun Wang
2  Department of Endocrinology and Metabolism, the Second Hospital of Shijiazhuang City, Shijiazhuang, Hebei Province, China
,
Zhiqiang Lu
1  Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
,
Yan Ling
1  Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
› Author Affiliations
Further Information

Publication History

received 07 April 2018
revised 10 May 2018

accepted 14 June 2018

Publication Date:
02 July 2018 (online)

Abstract

Purpose Homocysteine is associated with cardiovascular, inflammation and autoimmune diseases. Previous studies have shown that thyroid peroxidase antibody is associated with homocysteine levels in hypothyroidism. The relationship between thyroid antibodies and homocysteine in hyperthyroidism remains unclear. In this study, we aimed to investigate the association of thyroid antibodies with homocysteine in patients with Graves’ disease.

Methods This was a cross-sectional study including 478 Graves’ disease patients who were consecutively admitted and underwent radioiodine therapy. Homocysteine, thyroid hormones, thyroid antibodies, glucose and lipids were measured.

Results Patients with homocysteine levels above the median were older and had unfavorable metabolic parameters compared to patients with homocysteine levels below the median. Thyroglobulin antibody or thyroid peroxidase antibody was associated with homocysteine levels (β=0.56, 95%CI 0.03-1.08, p=0.04; β=0.75, 95%CI 0.23-1.27, p=0.005). The relationship between thyroid peroxidase antibody and homocysteine remained significant when additionally adjusting for free triiodothyronine (β=0.76, 95%CI 0.24-1.28, p=0.004). The presence of a homocysteine level above the median increased significantly with increasing thyroid peroxidase antibody quartiles in the logistic regression (OR=1.74, 95%CI 1.27-2.39, P for trend=0.001). Homocysteine levels increased significantly with increasing thyroid peroxidase antibody quartiles (p=0.005). Thyroid peroxidase antibody had no significant effect on other traditional cardiovascular risk factors.

Conclusions Thyroid peroxidase antibody is independently and positively associated with homocysteine levels in patients with Graves’ disease. Thyroid peroxidase antibody may be associated with the cardiovascular risk of patients with Graves’ disease through its effect on homocysteine.